LabRoots is pleased to announce the inauguration of the Immuno-Oncology Virtual Event taking place on June 2, 2021. Immuno-Oncology is considered by some to be one of the most promising areas of research in the world of anti-cancer therapeutics. Learn from our experts how immunotherapies can work alone, together, or in combination with other treatments to fight cancer.
This year's event includes the following tracks and topics:
New Advancements in Immuno-Oncology
Emerging Targets for Immuno-Oncology Therapy
Advancing Cancer Immunotherapies to the Clinic
Recent breakthroughs in immuno-oncology research translate into a paradigm shift with regards to attacking advancing cancer. The benefits of immuno-oncology have resulted in long-lasting tumor regression where surgery, radiotherapy, chemotherapy, and targeted therapy proved less effective.
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Like the 2020 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2021 Immuno-Oncology Virtual Event. Submission is free. Submit your abstract here.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Use #LRimmuno to follow the conversation!
Dr. Curran received a Ph.D. in Immunology from Stanford University where he was awarded the McDevitt prize for the best graduate thesis in his year. Dr. Curran was the first recipient of the prestigious American Cancer Society Levy Fellowship to fund his post-doctoral studies in the lab of Dr. James P. Allison. While pursuing his postdoctoral studies at Memorial Sloan-Kettering Cancer Center, Dr. Curran published several influential manuscripts describing how T cell co-stimulatory pathways could be modulated in tandem to mediate immunologic rejection of melanomas in mice. Dr. Curran was the first to describe how combination blockade of the T cell co-inhibitory receptors CTLA-4 and PD-1 promoted the rejection of a majority of murine melanomas – a combination that remains the most effective FDA-approved immunotherapy. At the MD Anderson Cancer Center, Dr. Curran is an Associate Professor of Immunology and his Lab seeks to discover the underlying mechanisms of immune resistance in the “coldest” tumors, pancreatic and prostate adenocarcinoma and glioblastoma, so that rational therapeutic interventions can be developed to restore T cell infiltration and sensitivity to T cell checkpoint blockade. This research focuses on normalization of tumor oxygen metabolism to increase T cell metabolic fitness, and on pro-inflammatory activation of tumor myeloid stroma.
Sigrun Badrnya is Manager in Product Development at the Thermo Fisher Scientific Center of Excellence for Immunoassays in Vienna, Austria. Sigrun received her PhD in vascular biology from the Medical University of Vienna in Austria. She continued as postdoctoral researcher at the Karolinska Institute in Stockholm, Sweden and within an industry-academia joint project for Randox Laboratories UK, where she focused on the development of multiplex protein biomarker assays. In her current role she is supervising an R&D team to develop immunoassays across diverse platforms including Invitrogen ELISA, ProcartaPlex and ProQuantum.
Dr. Burrack obtained B.S. in Biology at the University of Wisconsin and a M.S. in Physiology at the University of Wisconsin-La Crosse. He went on to complete his PhD in Immunology at the University of Colorado – Anschutz Medical Campus. Family history of both type 1 diabetes and pancreatic cancer have greatly influenced Dr. Burrack's scientific interests and research experiences. During graduate school, Dr. Burrack studied autoimmune diabetes recurrence and transplant recognition in a mouse model of type 1 diabetes in the laboratory of Ronald Gill. He then pursued post-doctoral at the University of Minnesota where he defined antigens that are recognized by alloreactive T cells direct transplant recognition. He also investigated how pancreatic beta cells respond to inflammation in the context of diabetes. With this background and specific interest in pancreatic diseases, he next joined the laboratory of Dr. Ingunn Stromnes at the University of Minnesota in the Center for Immunology. Over the past 3 years, he has developed novel mouse models of pancreatic cancer to interrogate the fate and functionality of tumor-specific T cells as well as mechanisms of immunotherapy resistance in the highly lethal disease, pancreatic cancer. This work has led to two first author publications in Cell Reports and Journal of Immunology. With these new models in hand, he is identifying novel strategies to enhance anti-tumor T cells in vivo to support pancreatic cancer eradication to inform clinical translation for pancreatic cancer patient treatment.
Wilco de Jager has a background in pediatric immunology and obtained his PhD at Utrecht University, in the Netherlands in 2008. During an 18 year academic career he built a biomarker laboratory using xMAP® Technology as the core technology. He joined Luminex in 2018 as a Senior Field Application Scientist with a particular interest in custom assay design for both academia and industry.
Mr. DeGolier obtained his B.S. in Biophysics at the University of Washington and is currently attending the University of Colorado – Anschutz Medical Campus to obtain his Ph.D. in Immunology. Between his undergraduate and graduate studies, Mr. DeGolier trained for several years with Dr. Courtney Crane at the Seattle Children’s Research Institute, working to characterize the tumor immune microenvironment in pediatric brain tumors, and to develop genetically engineered macrophages as a method to locally deliver immunomodulatory therapeutics within these tumors. Mr. DeGolier is presently training with Dr. Terry Fry, investigating the immunobiology of CAR T cells in the context of pediatric leukemias. His primary interests lie in studying the shortcomings in CAR T cell function that allow relapses to occur, and how T cell-intrinsic phenotypic heterogeneity contributes to functional differences in CAR T cell populations.
Dr. Leigh Ellis is the scientific director of the Center for Urologic Research Excellence at Cedars-Sinai Cancer and Acting Associate Professor of Medicine in the Division of Medical Oncology, Department of Medicine and Biomedical Sciences at Cedars-Sinai Medical Center. The Ellis lab focuses on dissecting underlying genetic/epigenetic mechanisms of aggressive prostate cancer. Our overall goal is to identify novel genomic/epigenomic mechanisms which will lead to discovery of biomarkers and therapeutic targets for clinical testing, with a specific focus on tumor and immune cell lineage plasticity in prostate cancer driven by the loss of the tumor suppressor protein, retinoblastoma-1 (RB) and collaboration with the histone modifying enzyme enhancer of zeste homolog-2 (EZH2).
Gordon J. Freeman, PhD is in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University.
Dr. Freeman’s research identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction. He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. This work provided the foundation for developing immune checkpoint blockade immunotherapies. He is a Fellow of the AACR Academy and received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology, 2017 Warren Alpert Foundation award, 2020 Richard Smalley, MD, memorial award from the Society for Immunotherapy of Cancer, and membership in the National Academy of Inventors for his work that led to development of PD-L1/PD-1 pathway blockade for cancer immunotherapy.
Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, with a joint appointment in the Department of Cancer Biology. Dr. Knutson serves as the Director of the Mayo Clinic in Florida Cell and Tissue Analysis Shared Resource. He is also Co-director of the Mayo Clinic Enterprise Cancer Center’s Cancer Immunology and Immunotherapy Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of Professor of Immunology, Mayo Clinic College of Medicine and Science. Dr. Knutson is recognized with the distinction of the Andrew A. and Mary S. Sugg Professor of Cancer Research. Dr. Knutson received his B.S. in Microbiology at the University of Washington. He earned his Ph.D. in Physiology and Pharmacology from the University of Georgia and completed two postdoctoral fellowships in immunology, one at the University of British Columbia and the other at the University of Washington. Dr. Knutson is internationally recognized in the field of cancer immunology. His research focuses on the immunology and immunotherapy of prevalent women’s cancer namely breast, ovarian, and lung cancers, both the basic immunobiology and clinical translation, including clinical trials. His contributions to science include clinical development and testing of tumor antigen-specific vaccines in patients with breast and ovarian cancers. He currently has 4 FDA-approved vaccine trials underway and is principal investigator of 3 Department of Defense grants and 1 NIH grant to test vaccines aimed at preventing recurrence of breast and ovarian cancer, including triple negative breast cancer for which there are no targeted therapies. Dr. Knutson is frequently invited to give presentations on his research both domestically and internationally, and he has authored numerous journal articles, abstracts and other written publications, consistently publishing in high-impact scientific journals. Additionally he holds reviewer responsibilities for several prominent publications. In recognition of his work, Dr. Knutson has received many awards and honors, including the Young Investigator Award-Pharmingen, conferred by the American Association for Cancer Research, and the prestigious Howard Temin Award, conferred by the National Institutes of Health, National Cancer Institute. He is also recognized as the 2017 Investigator of the Year at the Mayo Clinic campus in Florida. Additionally, he was just recently re-elected as a Komen Scholar for the second time for the period of 2019-2022. In addition to his research activities, Dr. Knutson is active in education and has mentored postdoctoral fellows, research associates and medical students, among others. He holds full faculty privileges in Immunology in Mayo Clinic Graduate School of Biomedical Sciences. Dr. Knutson’s has several current and past memberships with professional organizations which include the Breast Cancer Research Program and the Ovarian Cancer Research Program of the United States Department of Defense, the Tumor Microenvironment Study Section of the U.S. National Institutes of Health Center for Scientific Review, and the Education and Training Committee for the Society for the Immunotherapy of Cancer. He is the principal investigator of the Artemis Project, National Breast Cancer Coalition, where he is working to produce prevention vaccines for breast cancer.
Dave Mason is a Technical Specialist in Image Analysis supporting Visiopharm's UK and European Sales team. Trained as a Cell Biologist and Microbiologist he has spent over a decade in Academia specializing in Light Microscopy and Digital Image Analysis.
Brian McWilliams, Ph.D., received his undergraduate degree in Biochemistry from Oklahoma State University in 2001. His Ph.D. was completed with Dr. Joseph Petrosino at Baylor College of Medicine, where he studied vaccine design and diagnostics for bacterial pathogens Bacillus anthracis and Francisella tularensis. After a brief post-doc at The University of Texas – Medical Branch in Galveston, TX, he joined Bethyl Laboratories. He is currently the IP/WB Manager at Fortis Life Sciences, serving to maintain the existing catalog of Bethyl antibodies and validate new polyclonal and monoclonal antibody products from the R&D pipeline.
Dr. Dayana Rivadeneira is a research assistant professor in the Department of Immunology at the University of Pittsburgh. Dr. Rivadeneira received her Ph.D. in Genetics at Thomas Jefferson University where she explored mechanisms of cell cycle dysregulation in cancer. Her preclinical focus on CDK4/6 inhibition as a potential therapeutic target contributed to the launch of multiple clinical trials spanning several cancer types.During her postdoctoral years she examined the role of metabolism and mitochondrial dynamics in the tumor microenvironment and how it shapes anti-tumor immunity. Along these lines, her most recent efforts have centered on developing means by which the tumor microenvironment could be metabolically reprogrammed, with a specific focus on oncolytic viruses, as well as the effects of systemic metabolic disorders in immunotherapy response.
Leah Schmidt, PhD, is a postdoctoral fellow in the laboratory of Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center, and an AACR-AstraZeneca Immuno-oncology Research Fellow. Her research is focused on utilizing preclinical models for refining and improving engineered T cell therapies against solid tumors, including lung and pancreatic cancers. Prior to Fred Hutch, Dr. Schmidt completed her PhD thesis in the laboratory of Dr. Tyler Jacks at the Massachusetts Institute of Technology, where she studied the roles of natural killer cells in shaping anti-tumor immune responses in genetically engineered preclinical models. Her overarching scientific interest is uncovering strategies for improving patient outcomes by leveraging the immune system against human disease.
Dr. Peter Sullivan obtained his B.A. in Biology and Chemistry from Lake Forest College and his Ph.D. from Cornell University, studying the molecular biology underlaying the neurodegenerative diseases ALS and FTLD. After obtaining his Ph.D., he moved into CD8 T cell biology to better understand how the immune system functions in health and disease with the goal of applying this knowledge to novel cellular therapies. He is currently a post-doctoral fellow working with Dr. Rimas Orentas at Seattle Children's Research Institute. His research is focused on optimizing CAR T cell therapy for the treatment of pediatric solid tumors. Dr. Sullivan is excited to continue working in the emerging field of engineered cellular therapy.
I am a medical oncologist and hematologist, my clinical expertise is in melanoma and genitourinary malignancy, my clinical and translational research has been geared towards experimental therapeutics in renal cancer and melanoma. I serve as the Director for our Phase 1 Program at the Holden Comprehensive Cancer Center. Being at an NCI-designated Comprehensive Cancer Center offers me the resources to be on the cutting edge of cancer science and provides a unique opportunity to treat my patients on clinical trials at different phases. One of my main research projects has been an investigator initiated clinical trial combining high-dose selenium with axitinib in metastatic clear cell renal cell carcinoma. We presented the preliminary promising results at the American Urology Association 2020 Annual Meeting and we are in the process of putting a manuscript together. I also helped designing and leading a multi-center trial and protocol for a phase 1/2 clinical trial combining indoximod “an IDO inhibitor” with checkpoint inhibitors in metastatic melanoma patients. I had the honor of presenting the preliminary results of this trial at the American Association of Cancer Research (AACR) Annual Meeting Plenary Session in Washington, D.C, April 2017, and at the CRI-CIMT-EATI-AACR annual meeting in Frankfurt, Germany, September 2017, and the final results at the ASCO Annual Meeting, 2018.
Visiopharm® is a world leader in Augmented Pathology™ solutions; that comprise precision pathology and high-throughput pathology for tissue-diagnostics and research. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and ...See more See less
Sino Biological, Inc. is a global leader in manufacturing affordable, high-quality reagents, including recombinant proteins, antibodies and cDNA clones-all in-house. We provide a one-stop shop for researchers and pharmaceutical companies around the world, helping our customers ...See more See less
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The ...See more See less
For more than 30 years, GoldBio has been committed to researchers around the world. We know providing quality reagents to scientists leads to discoveries that benefit all. That is why we provide our customers with only the best chemicals, tested in GoldBio labs to ensure the ...See more See less
GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a ...See more See less
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic ...See more See less
OriGene Technologies was founded as a research tool company focused on the creation of the large commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based ...See more See less
Millipore Sigma is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis ...See more See less
BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Guided by our award-winning entrepreneurial leadership team, we ...See more See less
Miltenyi Biotec delivers solutions that advance biomedical research and cellular therapy. As the SARS-CoV-2 pandemic continues to take its toll around the world, Miltenyi Biotec stands committed to helping our customers navigate through this challenging time. With over 30 years ...See more See less
PerkinElmer is working closely with laboratories around the world to deliver the nucleic acid isolation, automation, real-time PCR, antibody testing, and NGS library preparation solutions they need to rapidly respond to the SARS-CoV-2 challenges both today and tomorrow. To ...See more See less
Bethyl Laboratories, Inc. has been dedicated to improving lives by supporting scientific discovery through its qualified antibody products and custom services since its founding in 1972. Bethyl has a global reputation for quality, consistency and first-class customer care. Every ...See more See less
Lunaphore is a Swiss firm born with the vision of bringing -omics like approaches to in-situ tissue analytics for cancer research and diagnostic purposes. Lunaphore develops innovative tissue staining platforms based on a cutting-edge technology, providing high quality results ...See more See less
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and ...See more See less
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
Tullia C. Bruno, PhD, is an Assistant Professor in the Department of Immunology at the University of Pittsburgh and a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. She obtained her Ph.D ...See more See less
Dr. Shannon Oda earned a Ph.D. in Immunology from the University of Colorado Anschutz Medical Campus and completed her postdoctoral training with Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center. She has received several awards, including the Evergreen Fund ...See more See less
Dr. Sater is a translational physician scientist (hematologist/oncologist) with special interest in immune therapy of cancer. He leads the Genitourinary Malignancies Branch efforts at understanding the role of cancer immunotherapy on the tumor (immune and non-immune) ...See more See less
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events
Research And Development
Labroots Registration (Also interested in)55%
WAVE Newsletter Promotion2%
Social Media Promotions1%
Medical Laboratory Technician6%
Clinical Laboratory Scientist3%
Life Science Company3%
Manufacturer - Other1%